The initiative aims to invest in or acquire small antibiotic companies developing new drugs and therapies. Slated for a formal announcement July 9, the coalition will involve drugmakers such as Eli Lilly, Pfizer, Merck, Boehringer Ingelheim and Bayer.
The venture builds upon the work being done by CARB-X, a public-private partnership formed in 2016 to fund antibiotic development as patients’ need for innovative treatments continues to grow.
More articles on pharmacy:
Cheap steroid in shortage after being posited as potential COVID-19 treatment
Regeneron paid patient charity millions in kickbacks, lawsuit claims
Novartis pays DOJ, SEC $347M in kickback scheme settlement
